Walleye Capital
RNAC icon

Walleye Capital’s Cartesian Therapeutics RNAC Stock Holding History

Walleye Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$853K Buy
+81,828
New +$606K ﹤0.01% 2263
2026
Q1 		– Sell
-43,878
Closed -$316K – 4902
2025
Q4 		$316K Buy
+43,878
New +$355K ﹤0.01% 3266
2020
Q2 		– Sell
-811
Closed -$59K – 912
2020
Q1 		$59K Buy
+811
New +$78.3K 0.01% 671
2019
Q2 		– Sell
-333
Closed -$24K – 1986
2019
Q1 		$24K Buy
+333
New +$21.1K ﹤0.01% 1327

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's RNAC Position: Q2 2026 in Review

Walleye Capital opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 81,828 shares worth $853K. The stake represents ﹤0.01% of the portfolio and ranks #2263 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RNAC as recently as Q4 2025.

Walleye Capital first reported a position in RNAC in Q1 2019 and has held it in 4 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Walleye Capital held 81,828 shares of Cartesian Therapeutics worth $853K as of Q2 2026.
  • Cartesian Therapeutics was a new Walleye Capital position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2263 holding.
  • Walleye Capital first reported a position in Cartesian Therapeutics in Q1 2019 and has held it in 4 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.